化学
结合
蒽环类
代谢物
小分子
作用机理
体内
药品
药物发现
组合化学
连接器
药理学
立体化学
生物化学
体外
乳腺癌
数学分析
生物技术
内科学
癌症
操作系统
生物
医学
计算机科学
数学
作者
Dane Holte,Joseph P. Lyssikatos,Amanda Valdiosera,Zachary Swinney,Vikram Sisodiya,Joseph Sandoval,Christina Lee,Monette Aujay,Robert Tchelepi,Omar Hamdy,Christine Gu,Baiwei Lin,Hetal Sarvaiya,Marybeth A. Pysz,Amy Laysang,Samuel A. Williams,Jeong Yong Lee,Magda K. Holda,James W. Purcell,Julia Gavrilyuk
标识
DOI:10.1016/j.bmcl.2020.127640
摘要
PNU-159682 is a highly potent secondary metabolite of nemorubicin belonging to the anthracycline class of natural products. Due to its extremely high potency and only partially understood mechanism of action, it was deemed an interesting starting point for the development of a new suite of linker drugs for antibody drug conjugates (ADCs). Structure activity relationships were explored on the small molecule which led to six linker drugs being developed for conjugation to antibodies. Herein we describe the synthesis of novel PNU-159682 derivatives and the subsequent linker drugs as well as the corresponding biological evaluations of the small molecules and ADCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI